Repligen stock was up more than 28% over the past three months coming into this report. Today it slipped about 2% in midday trade. That modest pullback sits awkwardly against what the quarter actually showed. Revenue reached about US$204.1m and organic growth hit 13%. Adjusted gross margin expanded to roughly 53.9% and adjusted operating margin moved to 16.7%, pointing to margin strength rather than strain.

If you own Repligen you are not trading a missed quarter. You are trading how much confidence you place in this margin story holding together from here.

Is Repligen now quietly mispriced, or does the premium P/S ratio suggest that the margin story is already reflected in the share price? Compare the current setup with our detailed valuation analysis for Repligen

Q2 2026 Earnings Summary

• Total Revenue, Q2 2026 vs. Q2 2025: US$204.1m vs. US$182.4m (up about 11.9%)
• Net Income, Q2 2026 vs. Q2 2025: US$5.0m vs. US$14.9m (down about 66.3%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.09 vs. US$0.26 (down about 66.4%)
• Adjusted Operating Margin, Q2 2026 vs. Q2 2025: 16.7% vs. about 12.1% (margin expansion of about 4.6 percentage points)

Tired of scrolling through earnings tables and margin figures trying to piece Repligen’s story together? Get a clear visual view of how the market is valuing the stock today and how that compares with its fundamentals in our company report for Repligen.

Repligen bull case: recurring engines and margin test

Bulls argue that Repligen is shifting toward a higher quality, recurring revenue mix with better margins and that this quarter needed to prove that is more than a story. The numbers help their case. Proteins grew about 50% and analytics more than 30%, both tied to consumables and services rather than one off equipment. Management raised full year organic growth guidance and still kept filtration only in mid single digits, which suggests the growth is coming from the franchises bulls want to see carrying more weight. Adjusted gross margin moved to 53.9% and adjusted operating margin to 16.7%, with guidance for further leverage even after higher Q3 and Q4 investment. That is a direct check mark against the margin expansion milestone bulls have focused on since the Polymem exit.

Repligen bear case: cyclicality, filtration drag and risk

Bears worry that Repligen is exposed to cyclical bioprocessing capex, customer concentration and filtration specific issues and that recent strength might be fragile. Q2 gives them mixed results. Filtration was only slightly higher and management still talks about inventory and a gene therapy customer issue, which supports the concern that this franchise carries operational noise. Net income moved down from US$14.9m to US$5.0m and basic EPS from US$0.26 to US$0.09, so reported profitability is not yet matching adjusted figures. The share price also slipped about 1.8% today after a roughly 28% gain over 90 days, which shows investors are not rushing to pay more for the stock on this update. However, raised full year revenue and EPS guidance, plus book to bill above 1 for capital equipment, work against the idea that demand is rolling over.

Compare how Repligen’s improving margin mix and cautious filtration outlook stack up against institutional expectations. See the consensus price target analysis for Repligen to check whether analysts think the current share price reflects this balance between progress and risk.

Stay Ahead With Simply Wall St

If Repligen’s margin story and premium P/S ratio have your attention, register for free with Simply Wall St and add it to your Watchlist to track price versus fair value and watch how the thesis develops. Once you take a position, keep your focus on what matters by using the Portfolio Command Center to cut through noise and surface key changes to revenue, margins and guidance. For a broader view on sentiment, use the Community to see how other investors are interpreting the same data and what they are watching next. This way you can spot potential catalysts and risks early and stay ahead of the market.

Seeking Alternatives Beyond Repligen?

Fresh stock ideas can move fast. Some lift off before the crowd catches the shift in momentum, while others drop off the radar for now. Scan these curated picks and consider them early in your research process.

• Use the curated 49 high quality undervalued stocks to explore companies with strong cash generation and balance sheets before they are widely watched.
• Explore the next wave of machine learning developments by focusing on profitable businesses through the carefully filtered 65 profitable AI stocks that aren't just burning cash while they still receive limited investor attention.
• Focus on resilient operators with low measured risk using the hand picked 83 resilient stocks with low risk scores before any change in sentiment draws more attention to these steadier stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.